Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Somford DM"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-6 z 6
    Tytuł:
    POSC399 Treatment Effect and Costs of the Complete Therapeutic Pathway in Patients with First-Line Castration-Resistant Prostate Cancer with Either First-Line Docetaxel or Abiraterone Acetate Plus Prednisone
    Autorzy:
    Holleman, MS
    Santi, I
    Huygens, S
    Aben, KKH
    Van den Bergh, ACM
    Bergman, AM
    van den Eertwegh, AJM
    Kuppen, MCP
    Lavalaye, J
    Mehra, NM
    van Moorselaar, RJA
    Van Oort, IM
    Somford, DM
    Westgeest, HM
    Gerritsen, WR
    Uyl-De Groot, CA
    Pokaż więcej
    Źródło:
    In Value in Health January 2022 25(1) Supplement:S266-S267
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Validation of Claims Data for Absorbing Pads as a Measure for Urinary Incontinence after Radical Prostatectomy, a National Cross-Sectional Analysis.
    Autorzy:
    Baas DJH; Department of Urology, Canisius Wilhelmina Hospital, 6532 SZ Nijmegen, The Netherlands.; Prosper Prostate Cancer Clinics, 6532 SZ Nijmegen, The Netherlands.
    Reitsma J; Zorgverzekeraars Nederland, 3700 AM Zeist, The Netherlands.
    Gerwen LV; Vektis Intelligence, Vektis, 3700 AS Zeist, The Netherlands.
    Vleghaar J; Vektis Intelligence, Vektis, 3700 AS Zeist, The Netherlands.
    Gehlen JMLG; CZ Zorgverzekeringen, 5038 KE Tilburg, The Netherlands.
    Ziedses des Plantes CMP; Zilveren Kruis, 3833 LB Leusden, The Netherlands.
    van Basten JPA; Department of Urology, Canisius Wilhelmina Hospital, 6532 SZ Nijmegen, The Netherlands.; Prosper Prostate Cancer Clinics, 6532 SZ Nijmegen, The Netherlands.
    van den Bergh RCN; Department of Urology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands.
    Bruins HM; Department of Urology, Zuyderland Medical Center, 6419 PC Heerlen, The Netherlands.
    Collette ERP; Department of Urology, Bravis Hospital, 4624 VT Bergen op Zoom, The Netherlands.
    Hoekstra RJ; Prosper Prostate Cancer Clinics, 6532 SZ Nijmegen, The Netherlands.; Department of Urology, Catharina Hospital Eindhoven, 5623 EJ Eindhoven, The Netherlands.
    Knipscheer BC; Department of Urology, Treant Zorggroep, 7824 AA Emmen, The Netherlands.
    van Leeuwen PJ; Department of Urology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
    Luijendijk-de Bruin D; Department of Urology, Martini Hospital, 9728 NT Groningen, The Netherlands.
    van Roermund JGH; Department of Urology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands.
    Sedelaar JPM; Prosper Prostate Cancer Clinics, 6532 SZ Nijmegen, The Netherlands.; Department of Urology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
    Speel TGW; Department of Urology, Leeuwarden Medical Center, 8934 AD Leeuwarden, The Netherlands.
    Stomps SP; Department of Urology, Ziekenhuisgroep Twente, 7609 PP Almelo, The Netherlands.
    Wijburg CJ; Department of Urology, Rijnstate Hospital, 6815 AD Arnhem, The Netherlands.
    Wijn RPWF; Department of Urology, Jeroen Bosch Hospital, 5223 GZ Hertogenbosch, The Netherlands.
    de Jong IJ; Department of Urology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
    Somford DM; Department of Urology, Canisius Wilhelmina Hospital, 6532 SZ Nijmegen, The Netherlands.; Prosper Prostate Cancer Clinics, 6532 SZ Nijmegen, The Netherlands.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2023 Dec 07; Vol. 15 (24). Date of Electronic Publication: 2023 Dec 07.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial.
    Autorzy:
    Exterkate L; Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
    Wegelin O; Department of Urology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
    Barentsz JO; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.
    van der Leest MG; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.
    Kummer JA; Department of Pathology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
    Vreuls W; Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
    de Bruin PC; Department of Pathology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
    Witjes JA; Department of Urology, Radboudumc, Nijmegen, The Netherlands.
    van Melick HHE; Department of Urology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
    Somford DM; Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
    Pokaż więcej
    Źródło:
    BJU international [BJU Int] 2023 Mar; Vol. 131 (3), pp. 313-320. Date of Electronic Publication: 2022 Sep 11.
    Typ publikacji:
    Randomized Controlled Trial; Multicenter Study; Journal Article
    MeSH Terms:
    Prostatic Neoplasms*/pathology
    Male ; Humans ; Magnetic Resonance Imaging/methods ; Prospective Studies ; Incidence ; Biopsy ; Image-Guided Biopsy/methods ; Retrospective Studies
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.
    Autorzy:
    Hermsen R; Department of Nuclear Medicine, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
    Wedick EBC; Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
    Vinken MJM; Department of Nuclear Medicine, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
    van Kalmthout LWM; Department of Nuclear Medicine, University Medical Center, Utrecht, The Netherlands.
    Küsters-Vandevelde HVN; Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
    Wijers CHW; CWZ Academy, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
    Somford DM; Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.; Prosper Prostate Cancer Clinics, Nijmegen, The Netherlands.
    van Basten JA; Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands. .; Prosper Prostate Cancer Clinics, Nijmegen, The Netherlands. .
    Pokaż więcej
    Źródło:
    European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2022 Sep; Vol. 49 (11), pp. 3929-3937. Date of Electronic Publication: 2022 May 11.
    Typ publikacji:
    Clinical Trial; Journal Article
    MeSH Terms:
    Positron Emission Tomography Computed Tomography*/methods
    Prostatic Neoplasms*/diagnostic imaging
    Prostatic Neoplasms*/surgery
    Fluorine Radioisotopes ; Gallium Radioisotopes ; Humans ; Lymph Nodes/pathology ; Lymphatic Metastasis/diagnostic imaging ; Male ; Neoplasm Staging ; Prostate/pathology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Autorzy:
    Boerrigter E; Radboud University Medical Center, Department of Pharmacy, Radboud Institute for Health Sciences, 6525 GA Nijmegen, The Netherlands.
    Benoist GE; Radboud University Medical Center, Department of Pharmacy, Radboud Institute for Health Sciences, 6525 GA Nijmegen, The Netherlands.
    van Oort IM; Radboud University Medical Center, Department of Urology, Radboud Institute for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands.
    Verhaegh GW; Radboud University Medical Center, Department of Urology, Radboud Institute for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands.
    de Haan AFJ; Radboud University Medical Center, Department for Health Evidence, Biostatistics, 6525 GA Nijmegen, The Netherlands.
    van Hooij O; Radboud University Medical Center, Department of Urology, Radboud Institute for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands.
    Groen L; Radboud University Medical Center, Department of Urology, Radboud Institute for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands.
    Smit F; MDxHealth, 6534 AT Nijmegen, The Netherlands.
    Oving IM; Department of Medical Oncology, Ziekenhuisgroep Twente, 7609 PP Almelo, The Netherlands.
    de Mol P; Department of Medical Oncology, Gelderse Vallei Hospital, 6716 RP Ede, The Netherlands.
    Smilde TJ; Department of Medical Oncology, Jeroen Bosch Hospital, 5223 GZ 's-Hertogenbosch, The Netherlands.
    Somford DM; Department of Urology, Canisius Wilhelmina Hospital, 6532 SZ Nijmegen, The Netherlands.
    Hamberg P; Department of Medical Oncology, Franciscus Gasthuis & Vlietland, 3045 PM Rotterdam, The Netherlands.
    Dezentjé VO; Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
    Mehra N; Radboud University Medical Center, Department of Medical Oncology, 6525 GA Nijmegen, The Netherlands.
    van Erp NP; Radboud University Medical Center, Department of Pharmacy, Radboud Institute for Health Sciences, 6525 GA Nijmegen, The Netherlands.
    Schalken JA; Radboud University Medical Center, Department of Urology, Radboud Institute for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2021 Dec 14; Vol. 13 (24). Date of Electronic Publication: 2021 Dec 14.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Functional and oncological outcomes of salvage cryosurgery for radiorecurrent prostate cancer.
    Autorzy:
    Exterkate L; Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
    Peters M; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
    Somford DM; Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
    Vergunst H; Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
    Pokaż więcej
    Źródło:
    BJU international [BJU Int] 2021 Jul; Vol. 128 (1), pp. 46-56. Date of Electronic Publication: 2020 Nov 04.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Cryosurgery*
    Neoplasm Recurrence, Local/*surgery
    Prostatic Neoplasms/*surgery
    Aged ; Humans ; Male ; Middle Aged ; Prostatic Neoplasms/radiotherapy ; Retrospective Studies ; Salvage Therapy ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-6 z 6

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies